ProBioGen and Spica Therapeutics, a biotechnology company advancing pathogenic macrophage subset-targeted immunotherapies, ...

The renewed agreement supports Merck’s efforts to integrate AI more deeply into its scientific workflows. With ongoing access ...

Cellular Origins, a company that enables the manufacturing of cell therapies at scale, has completed a $40 million ...

Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma for the development, ...

Mirum Pharmaceuticals Inc. has agreed to acquire Bluejay Therapeutics, a privately held biotechnology company focused on ...

Natera Inc., a cell-free DNA and precision medicine company, has acquired Foresight Diagnostics, a leader in ultrasensitive ...

Quotient Sciences and Intrepid Labs have announced a multi-year strategic partnership to advance the use of artificial ...

Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Daniel J. O'Connor as President & Chief ...

CDMOs have become structural pillars of drug development, keeping pipelines moving, absorbing operational shocks, and turning ...

As 2026 approaches, the clinical research and development landscape is evolving beyond traditional scientific innovation with ...

Vetter, a globally leading CDMO, announced the retirement of its Managing Director, Thomas Otto, after over 35 years at the ...

Neurimmune has expanded its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, an AstraZeneca company ...